A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.
This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.
The trial will enrol up to 50 healthy volunteers aged 18 to 49. Three groups of study participants (10 participants each) will be vaccinated with 10, 25 and 50 micrograms of the experimental vaccine, respectively. The study also will include a group of participants who will receive a current quadrivalent seasonal influenza vaccine.
This will allow the researchers a point of direct comparison between the immunogenicity and safety of the candidate vaccine and available seasonal flu vaccines. Participants will be regularly evaluated to assess the vaccine’s safety (and, secondarily, its efficacy) and will receive follow-up appointments for up to one year after vaccination.
Issues with current flu vaccines
Although annual seasonal flu vaccines are valuable tools in controlling the spread and severity of influenza, they do not provide immunity against every flu strain. Each year, scientific experts predict which influenza strains are likely to be most common. It takes time to produce the vaccine, during which time these strains could change.
An effective universal flu vaccine could eliminate these problems by protecting its recipients against a wide variety of strains and ideally providing durable long-term immunity, so people would not need to be vaccinated every year.
“A universal influenza vaccine would be a major public health achievement and could eliminate the need for both annual development of seasonal influenza vaccines, as well as the need for patients to get a flu shot each year,” said Acting NIAID Director Hugh Auchincloss. “Moreover, some strains of influenza virus have significant pandemic potential. A universal flu vaccine could serve as an important line of defence against the spread of a future flu pandemic.”
The early-stage trial is being conducted through the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, which was created by NIAID in 2019 to support the development of broadly protective and longer-lasting flu vaccines.
A similar vaccine developed by researchers at NIAID’s VRC has already shown positive results in early clinical trials. Both vaccines use a specific portion of a flu protein, hemagglutinin (HA), to induce a broad immune response against influenza.
While one portion of the HA protein, known as the head, tends to change as the flu virus spreads and evolves, a more stable portion, known as the stem, evolves very slowly and is very similar across many different types of the flu virus. By using the HA stem as the basis for a vaccine, researchers hope to induce long-term immunity against a broad range of flu viruses.
Unlike the VRC’s earlier vaccine, the H1ssF-3928 mRNA-LNP vaccine candidate uses a messenger RNA (mRNA) platform. By developing and testing a variety of different platforms for a universal flu vaccine, researchers are more likely to find one that is both safe and provides strong and broad immunity against a variety of strains.